The precise mode of action of D(-)penicillamine in rheumatoid arthritis is still unknown although its ability to reduce the titre of rheumatoid factor is well established (Dresner and Trombly, 1960; Griffin, Ulloa, Henry, Johnston, and Holley, 1960; Jaffe, 1962 Jaffe, , 1963 . Its efficacy in the treatment of rheumatoid disease was indicated in Britain, first by a pilot study (Golding, Wilson, and Day, 1970) and subsequently by a 12-month double-blind study (Multicentre Trial Group, 1973) . The original patients were reported (Day, Golding, Lee, and Butterworth, 1974) after treatment had extended in some instances for as long as 5 years. The authors concluded that smaller doses of penicillamine than are usually advocated are often effective and cause fewer adverse reactions.
Patients and methods A double-blind controlled multicentre trial comparing the therapeutic effect and adverse effects of penicillamine in a dosage ofeither 600 mg or 1 200 mg daily in patients under fixed standard treatment is reported. A third group of patients acted as a control group, receiving the standard treatment and a minimal subeffective dose ofpenicillamine (12 mg daily).
The penicillamine base used was wholly synthetic*; it is prepared by a multistage synthesis from the appropriate amino acid precursor as opposed to semisynthetic penicillamine which is prepared by the acid hydrolysis of benzylpenicillin. The material contains 0-3 % of the optical isomer, L(+)penicillamine, which is regarded as toxic.
Outpatients at 5 hospital centres over the age of 16 years and having seropositive erosive disease classifiable as 'classical' or 'definite' (ARA, 1959) were studied. Informed consent was obtained from them after the purpose of the study was explained. 
Results
In the final assessment of the efficacy of penicillamine, results from the general group and the nodule group were combined. Table I shows the comparability of the three treatment subgroups at the start of the trial. (1) Patients' pain assessment (Table II) Wilcoxon's signed rank sum test was also used since this method of grading pain is nonparametric, and the results obtained were similar. In Table II (6) Haemoglobin Serum copper values fell significantly as expected in the patients receiving penicillamine as compared with the C group at both 12 and 24 weeks. (P < 0 01 and P < 0-05, respectively). At 12 weeks the patients in the 1200 group had significantly lower serum copper values than those receiving the smaller dose (600 group), but by 24 weeks the difference was no longer significant.
Serum zinc values showed no significant changes. SGOT, alkaline phosphatase, and serum bilirubin estimations, made on all patients frequently throughout the trial, showed no evidence of variation outside normal limits.
ADVERSE REACTIONS AND WITHDRAWALS FROM THE TRIAL
Information on adverse reactions was elicited by use of a standard nonleading question and all symptoms which were not clearly unrelated to treatment were so classified (Table VII) . One patient in the 600 group developed neutropenia (absolute count 294/mm3) and there were 3 in the 1200 group with mild thrombocytopenia. Two of these also had some neutropenia (absolute counts 1050 and 1728). All were withdrawn from the trial and their blood counts rapidly returned to normal after stopping penicillamine. Abnormalities of taste (often with nausea and vomiting), rashes, and blood dyscrasias were the cause of all but two withdrawals due to adverse reactions. One exception was withdrawn from the 600 group because of proteinuria (100 mg/100 ml) and the other from the 1200 group due to diarrhoea and buccal ulcers within a day or two of completing the trial.
Four patients were withdrawn for other reasons.
One patient in the 1200 group developed pernicious anaemia and another in the same group could not continue in the trial because of transport difficulties. One patient in the 600 group was withdrawn because of a pyrexial illness, probably influenza, and the remaining patient in the C group developed atrial fibrillation and congestive cardiac failure. Two other patients in the C group died of myocardial infarction during the trial.
Discussion
This study confirms previous findings (Multicentre Trial Goup, 1973; Day and others, 1974 ) that D(-)penicillamine is of therapeutic value in rheumatoid arthritis. Doses of both 600 and 1200 mg daily added to standard treatment produced statistically significant improvement in relief of pain, grip strength, ESR, and haemoglobin. Improvement usually began between 4 to 8 weeks after starting treatment, but was often not complete until at least 12 weeks or more had elapsed. Duration of disease did not appear to affect therapeutic response and there was no evidence of significant change in x-rays of the hands or feet, or in the size or number of rheumatoid nodules during the 6 months of the trial.
The type and extent of adverse reactions were similar to those reported by other authors. Three patients in C group complained of abnormality of taste or of a 'metallic' taste, but it is likely that these symptoms were related to discussion with other patients in the trial than to the daily dose of 12 mg penicillamine the group was receiving. One patient only was withdrawn because of proteinuria, probably related to the relative shortness of the trial since immune-complex nephropathy is often a later complication. However, there were only two other patients with mild proteinuria, a total frequency of 2-5 %.
Significant overall dosage-related effects occurred not only with regard to the extent of improvement and the number of patients improving, but also to the frequency of adverse reactions. At no time, however, did the differences between the high and low dose groups attain statistical significance when analysed separately. It is therefore necessary to examine the therapeutic implications of this situation. Table VI shows that 70% of patients in the 1200 group improved (taking grip strength as representative of the 3 clinical parameters assessed in this way) compared with 56% of those in the 600 group. The standard error of the difference between the percentages is 13 % and therefore, with confidence limits of 95 %, the true difference lay between -12 % and +40 % (14 ± 2 x 13). A similar calculation for the number of patients suffering adverse reactions in the two groups gave -9 % to +43 %. The implications of this are that a change in dosage from 600 to 1200 mg daily could produce a result varying from a small decrease to a large increase both in improvement and adverse reactions, though the extremes of these changes would not of course necessarily correlate with each other. Furthermore it must be recalled that the figures given in Table VI the increasing sophistication of way of life (Popert and Hewitt, 1962; Rose and Prior, 1963) . A further step will be to study the relationship between SUA concentrations and common disease processes, which also have a changing prevalence. Similarly, potential environmental determinants of SUA concentrations will be selected for scrutiny to establish the extent of their influence upon this course ofevents.
The earlier surveys of rural and urban African communities were made under the aegis of Professor Louis Solomon, Department of Orthopaedic Surgery, University of the Witwatersrand, Johannesburg.
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